Charles River Laboratories International, Inc. (CRL)
USD 183.16
(-3.26%)
USD 183.16
(-3.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 885.29 Million USD | 9.07% |
| 2022 | 811.67 Million USD | 8.98% |
| 2021 | 744.77 Million USD | 16.22% |
| 2020 | 640.81 Million USD | 5.54% |
| 2019 | 607.16 Million USD | 19.36% |
| 2018 | 508.68 Million USD | 22.63% |
| 2017 | 414.81 Million USD | 1.36% |
| 2016 | 409.24 Million USD | 26.06% |
| 2015 | 324.64 Million USD | 10.05% |
| 2014 | 294.99 Million USD | 21.15% |
| 2013 | 243.5 Million USD | 7.59% |
| 2012 | 226.31 Million USD | -0.71% |
| 2011 | 227.93 Million USD | -20.55% |
| 2010 | 286.89 Million USD | 9.32% |
| 2009 | 262.44 Million USD | 0.76% |
| 2008 | 260.47 Million USD | 3.77% |
| 2007 | 251 Million USD | 14.91% |
| 2006 | 218.43 Million USD | -11.82% |
| 2005 | 247.71 Million USD | 79.19% |
| 2004 | 138.24 Million USD | 45.35% |
| 2003 | 95.11 Million USD | 9.68% |
| 2002 | 86.71 Million USD | 12.67% |
| 2001 | 76.96 Million USD | 9.84% |
| 2000 | 70.07 Million USD | 26.47% |
| 1999 | 55.4 Million USD | 56.39% |
| 1998 | 35.42 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 165.85 Million USD | -6.41% |
| 2024 Q1 | 177.21 Million USD | -23.34% |
| 2023 Q4 | 231.16 Million USD | 9.9% |
| 2023 Q3 | 210.33 Million USD | -10.12% |
| 2023 Q2 | 234.03 Million USD | 11.57% |
| 2023 FY | 885.29 Million USD | 9.07% |
| 2023 Q1 | 209.76 Million USD | -10.77% |
| 2022 Q1 | 188.04 Million USD | 7.88% |
| 2022 Q3 | 219.24 Million USD | 68.94% |
| 2022 Q4 | 235.07 Million USD | 7.22% |
| 2022 FY | 811.67 Million USD | 8.98% |
| 2022 Q2 | 129.78 Million USD | -30.98% |
| 2021 Q3 | 181.42 Million USD | -11.27% |
| 2021 Q1 | 184.57 Million USD | 7.91% |
| 2021 Q4 | 174.3 Million USD | -3.92% |
| 2021 FY | 744.77 Million USD | 16.22% |
| 2021 Q2 | 204.47 Million USD | 10.78% |
| 2020 Q2 | 155.47 Million USD | -1.46% |
| 2020 FY | 640.81 Million USD | 5.54% |
| 2020 Q4 | 171.04 Million USD | 9.28% |
| 2020 Q3 | 156.52 Million USD | 0.68% |
| 2020 Q1 | 157.78 Million USD | 2.77% |
| 2019 Q4 | 153.52 Million USD | 0.14% |
| 2019 Q1 | 141.98 Million USD | 14.56% |
| 2019 Q2 | 158.33 Million USD | 11.52% |
| 2019 Q3 | 153.31 Million USD | -3.17% |
| 2019 FY | 607.16 Million USD | 19.36% |
| 2018 FY | 508.68 Million USD | 22.63% |
| 2018 Q3 | 131.83 Million USD | -5.34% |
| 2018 Q4 | 123.93 Million USD | -5.99% |
| 2018 Q2 | 139.27 Million USD | 22.55% |
| 2018 Q1 | 113.64 Million USD | 8.21% |
| 2017 Q3 | 103.22 Million USD | -1.08% |
| 2017 Q2 | 104.35 Million USD | 2.08% |
| 2017 Q1 | 102.22 Million USD | -7.73% |
| 2017 Q4 | 105.01 Million USD | 1.74% |
| 2017 FY | 414.81 Million USD | 1.36% |
| 2016 Q4 | 110.79 Million USD | 13.66% |
| 2016 Q1 | 89.29 Million USD | 1.12% |
| 2016 Q3 | 97.47 Million USD | -12.72% |
| 2016 Q2 | 111.68 Million USD | 25.07% |
| 2016 FY | 409.24 Million USD | 26.06% |
| 2015 FY | 324.64 Million USD | 10.05% |
| 2015 Q1 | 76.65 Million USD | -3.19% |
| 2015 Q2 | 77.04 Million USD | 0.51% |
| 2015 Q3 | 82.63 Million USD | 7.25% |
| 2015 Q4 | 88.3 Million USD | 6.86% |
| 2014 Q2 | 74.6 Million USD | 7.96% |
| 2014 Q4 | 79.17 Million USD | 9.82% |
| 2014 FY | 294.99 Million USD | 21.15% |
| 2014 Q1 | 69.1 Million USD | 8.68% |
| 2014 Q3 | 72.09 Million USD | -3.37% |
| 2013 FY | 243.5 Million USD | 7.59% |
| 2013 Q4 | 63.58 Million USD | 7.62% |
| 2013 Q3 | 59.08 Million USD | -0.5% |
| 2013 Q2 | 59.38 Million USD | -3.36% |
| 2013 Q1 | 61.44 Million USD | 9.81% |
| 2012 Q2 | 54.31 Million USD | -10.19% |
| 2012 FY | 226.31 Million USD | -0.71% |
| 2012 Q3 | 55.57 Million USD | 2.33% |
| 2012 Q1 | 60.47 Million USD | 17.58% |
| 2012 Q4 | 55.95 Million USD | 0.68% |
| 2011 Q1 | 60.38 Million USD | 3.09% |
| 2011 Q2 | 53 Million USD | -12.22% |
| 2011 Q3 | 55.62 Million USD | 4.94% |
| 2011 Q4 | 51.42 Million USD | -7.54% |
| 2011 FY | 227.93 Million USD | -20.55% |
| 2010 Q2 | 72.16 Million USD | 2.48% |
| 2010 FY | 286.89 Million USD | 9.32% |
| 2010 Q1 | 70.41 Million USD | 3.25% |
| 2010 Q3 | 85.74 Million USD | 18.82% |
| 2010 Q4 | 58.57 Million USD | -31.68% |
| 2009 FY | 262.44 Million USD | 0.76% |
| 2009 Q1 | 68.32 Million USD | 8.68% |
| 2009 Q2 | 63.8 Million USD | -6.62% |
| 2009 Q3 | 62.11 Million USD | -2.64% |
| 2009 Q4 | 68.19 Million USD | 9.79% |
| 2008 Q4 | 62.87 Million USD | 1.31% |
| 2008 FY | 260.47 Million USD | 3.77% |
| 2008 Q3 | 62.05 Million USD | -9.62% |
| 2008 Q2 | 68.66 Million USD | 2.67% |
| 2008 Q1 | 66.87 Million USD | 1.9% |
| 2007 Q2 | 64.23 Million USD | 5.52% |
| 2007 FY | 251 Million USD | 14.91% |
| 2007 Q1 | 60.87 Million USD | 7.59% |
| 2007 Q3 | 60.26 Million USD | -6.17% |
| 2007 Q4 | 65.62 Million USD | 8.9% |
| 2006 Q4 | 56.57 Million USD | 12.39% |
| 2006 Q1 | 188.14 Million USD | 171.62% |
| 2006 Q2 | 59.4 Million USD | -68.42% |
| 2006 FY | 218.43 Million USD | -11.82% |
| 2006 Q3 | 50.34 Million USD | -15.26% |
| 2005 Q1 | 59.21 Million USD | 12.81% |
| 2005 Q2 | 61.93 Million USD | 4.59% |
| 2005 Q3 | 57.29 Million USD | -7.48% |
| 2005 Q4 | 69.26 Million USD | 20.89% |
| 2005 FY | 247.71 Million USD | 79.19% |
| 2004 FY | 138.24 Million USD | 45.35% |
| 2004 Q1 | 29.31 Million USD | 21.31% |
| 2004 Q2 | 30.41 Million USD | 3.78% |
| 2004 Q3 | 26.02 Million USD | -14.45% |
| 2004 Q4 | 52.49 Million USD | 101.71% |
| 2003 FY | 95.11 Million USD | 9.68% |
| 2003 Q3 | 22.23 Million USD | -9.53% |
| 2003 Q4 | 24.16 Million USD | 8.67% |
| 2003 Q1 | 24.13 Million USD | 8.74% |
| 2003 Q2 | 24.57 Million USD | 1.84% |
| 2002 Q4 | 22.19 Million USD | 5.91% |
| 2002 Q3 | 20.95 Million USD | -4.82% |
| 2002 Q2 | 22.01 Million USD | 2.18% |
| 2002 Q1 | 21.54 Million USD | 1.63% |
| 2002 FY | 86.71 Million USD | 12.67% |
| 2001 Q1 | 17.28 Million USD | -16.28% |
| 2001 FY | 76.96 Million USD | 9.84% |
| 2001 Q4 | 21.2 Million USD | 10.44% |
| 2001 Q3 | 19.19 Million USD | -0.41% |
| 2001 Q2 | 19.27 Million USD | 11.51% |
| 2000 FY | 70.07 Million USD | 26.47% |
| 2000 Q4 | 20.65 Million USD | 30.66% |
| 2000 Q3 | 15.8 Million USD | 11.33% |
| 2000 Q1 | 19.42 Million USD | 0.0% |
| 2000 Q2 | 14.19 Million USD | -26.9% |
| 1999 FY | 55.4 Million USD | 56.39% |
| 1998 FY | 35.42 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agilent Technologies, Inc. | 2.11 Billion USD | 58.142% |
| Quest Diagnostics Incorporated | 1.61 Billion USD | 45.013% |
| Danaher Corporation | 8.83 Billion USD | 89.976% |
| Enzo Biochem, Inc. | 26.99 Million USD | -3179.235% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 56.878% |
| Laboratory Corporation of America Holdings | 2.02 Billion USD | 56.204% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 18.735% |
| Qiagen N.V. | 777.67 Million USD | -13.838% |
| Revvity, Inc. | 874.01 Million USD | -1.29% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 91.366% |
| Waters Corporation | 943.51 Million USD | 6.171% |